Oric(ORIC) - 2024 Q3 - Quarterly Results

Exhibit 99.1 ORIC® Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operational Updates Presented preclinical data further supporting the potential best-in-class profile of ORIC-114 to treat EGFR exon 20 insertions and other atypical mutations at the EORTC-NCI-AACR Conference Announced clinical collaborations with multiple strategic partners to support ongoing trial evaluating ORIC944 in combination with AR inhibitors for the treatment of prostate cancer Cash and investments of $282.4 millio ...